The board of Eikon Therapeutics will soon look like Merck & Co's a few years ago – after the big pharma's former CEO Ken Frazier agree to join his former colleagues Roger Perlmutter and
Merck & Co's chief medical officer and head of clinical development Dr Roy Baynes has announced his retirement from the company to take up a new role alongside his former colleague Roge
